Your browser doesn't support javascript.
loading
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot, X; Bondarenko, I; Nowecki, Z; Dvorkin, M; Trishkina, E; Ahn, J-H; Im, S-A; Sarosiek, T; Chatterjee, S; Wojtukiewicz, M Z; Shparyk, Y; Moiseyenko, V; Bello, M; Semiglazov, V; Lee, Y; Lim, J.
Afiliación
  • Pivot X; Administrateur de l'Institut Régional du Cancer, 3 rue de la porte de l'hôpital, BP 30042, 67065, Strasbourg Cedex, France. Electronic address: xpivot@strasbourg.unicancer.fr.
  • Bondarenko I; Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine.
  • Nowecki Z; Department of Oncology, M Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Dvorkin M; Department of Oncology, Clinical Oncology Dispensary, Omsk, Russia.
  • Trishkina E; Department of Oncology, Leningrad Regional Oncology Centre, St. Petersburg, Russia.
  • Ahn JH; Department of Oncology, Asan Medical Center, Seoul, Republic of Korea.
  • Im SA; Department of Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Sarosiek T; Department of Clinical Oncology, Centrum Medyczne Ostrobramska NZOZ MAGODENT, Warsaw, Poland.
  • Chatterjee S; Department of Oncology, Tata Medical Centre, Kolkata, India.
  • Wojtukiewicz MZ; Department of Oncology, Medical University of Bialystok, Bialystok, Poland.
  • Shparyk Y; Chemotherapy Department, Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine.
  • Moiseyenko V; Department of Oncology, N.N. Petrov Cancer Center, St. Petersburg, Russia.
  • Bello M; Department of Oncology, Saint Luke's Medical Center, Quezon City, Philippines.
  • Semiglazov V; Department of Oncology, N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia.
  • Lee Y; Biometrics Group (Y. Lee) and Clinical Development Group (J. Lim), Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
  • Lim J; Biometrics Group (Y. Lee) and Clinical Development Group (J. Lim), Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
Eur J Cancer ; 93: 19-27, 2018 04.
Article en En | MEDLINE | ID: mdl-29448072
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido